Form 8-K - Current report:
SEC Accession No. 0000950170-25-069818
Filing Date
2025-05-13
Accepted
2025-05-13 08:05:08
Documents
13
Period of Report
2025-05-13
Items
Item 2.02: Results of Operations and Financial Condition

Document Format Files

Seq Description Document Type Size
1 8-K atos-20250513.htm   iXBRL 8-K 56329
2 EX-99.1 atos-ex99_1.htm EX-99.1 247329
3 GRAPHIC img248274862_0.jpg GRAPHIC 5299
  Complete submission text file 0000950170-25-069818.txt   446221

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20250513.xsd EX-101.SCH 28515
15 EXTRACTED XBRL INSTANCE DOCUMENT atos-20250513_htm.xml XML 4681
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

EIN.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35610 | Film No.: 25937237
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)